This result is consistent with a previous study, that demonstrated that dapagliflozin can protect against steatosis through the inhibition of NLRP3 inflammasome resulting in the reduction of high triglycerides, free fatty acids, and blood sugar in HFD [20]. The gene discussed is NLRP3; the disease is steatosis.